{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:49:22Z","timestamp":1778806162375,"version":"3.51.4"},"reference-count":61,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Griffith University Postdoctoral Fellowship (GUPF; MLS)"},{"name":"Drugs for Neglected Diseases initiative (DNDi)"},{"name":"the Swiss Agency for Development and Cooperation (SDC)"},{"name":"the Directorate General for International Cooperation (DGIS)"},{"name":"(DFID), UK and M\u00e9decins Sans Fronti\u00e8res, international"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Chagas disease caused by the protozoan Trypanosoma cruzi is endemic to 21 countries in the Americas, effects approximately 6 million people and on average results in 12,000 deaths annually. Human African Trypanosomiasis (HAT) is caused by the Trypanosoma brucei sub-species, endemic to 36 countries within sub-Saharan Africa. Treatment regimens for these parasitic diseases are complicated and not effective against all disease stages; thus, there is a need to find improved treatments. To identify new molecules for the drug discovery pipelines for these diseases, we have utilised in vitro assays to identify compounds with selective activity against both T. cruzi and T.b. brucei from the Medicines for Malaria Venture (MMV) Pathogen Box compound collection. To prioritise these molecules for further investigation, temporal and wash off assays were utilised to identify the speed of action and cidality of compounds. For translational relevance, compounds were tested against clinically relevant T.b. brucei subspecies. Compounds with activity against T. cruzi cytochrome P450 (TcCYP51) have not previously been successful in clinical trials for chronic Chagas disease; thus, to deprioritise compounds with this activity, they were tested against recombinant TcCYP51. Compounds with biological profiles warranting progression offer important tools for drug and target development against kinetoplastids.<\/jats:p>","DOI":"10.3390\/microorganisms10071287","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T21:01:41Z","timestamp":1656277301000},"page":"1287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9379-9012","authenticated-orcid":false,"given":"Melissa L.","family":"Sykes","sequence":"first","affiliation":[{"name":"Discovery Biology, Griffith University, Nathan, QLD 4111, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily K.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Discovery Biology, Griffith University, Nathan, QLD 4111, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[{"name":"Wellcome Centre for Anti-Infective Research, Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Swiss Tropical and Public Health Institute (Swiss TPH), 4123 Allschwil, Switzerland"},{"name":"University of Basel, 4002 Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4914-2299","authenticated-orcid":false,"given":"Vicky M.","family":"Avery","sequence":"additional","affiliation":[{"name":"Discovery Biology, Griffith University, Nathan, QLD 4111, Australia"},{"name":"School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organisation (2022, May 27). Neglected Tropical Diseases. Available online: https:\/\/www.who.int\/health-topics\/neglected-tropical-diseases."},{"key":"ref_2","unstructured":"World Health Organisation (2022, May 27). Chagas Disease (American trypanosomiasis). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis)."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas\u2019 disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4269\/ajtmh.16-0761","article-title":"Experimental and Clinical Treatment of Chagas Disease: A Review","volume":"97","author":"Molina","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_6","unstructured":"Drugs for Neglected Diseases Initiative (2022, May 27). Fexinidazole for T.b. rhodesiense. Available online: https:\/\/dndi.org\/research-development\/portfolio\/fexinidazole-tb-rhodesiense\/."},{"key":"ref_7","unstructured":"(2022, May 27). Efficacy and Safety of Fexinidazole in Patients with Human African Trypanosomiasis (HAT) Due to Trypanosoma brucei rhodesiense, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03974178."},{"key":"ref_8","unstructured":"World Health Organization (1998). Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee, World Health Organisation Technical Report Series."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd3375","article-title":"Trial Watch Phase III and submission failures: 2007\u20132010","volume":"10","author":"Arrowsmith","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","unstructured":"(2022, May 27). MMV About the Pathogen Box. Available online: https:\/\/www.mmv.org\/mmv-open\/pathogen-box\/about-pathogen-box."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/embr.201438652","article-title":"Tropical diseases and the poor: Neglected tropical diseases are a public health problem for developing and developed countries alike","volume":"15","author":"Hunter","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13071-019-3747-6","article-title":"Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery","volume":"12","author":"Maccesi","year":"2019","journal-title":"Parasit Vectors"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpddr.2019.06.004","article-title":"Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites","volume":"10","author":"Nugraha","year":"2019","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e02006-16","DOI":"10.1128\/AAC.02006-16","article-title":"Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors","volume":"61","author":"Vila","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02373-18","DOI":"10.1128\/AAC.02373-18","article-title":"Screening the Pathogen Box for Identification of New Chemical Agents with Anti-Fasciola hepatica Activity","volume":"63","author":"Machicado","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1128\/AAC.00379-17","article-title":"Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery","volume":"61","author":"Duffy","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1039\/C8MD00319J","article-title":"Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery","volume":"9","author":"Veale","year":"2018","journal-title":"MedChemComm"},{"key":"ref_18","unstructured":"World Health Organisation (2022, May 27). Human African Trypanosomiasis (Sleeping Sickness). Available online: https:\/\/www.who.int\/health-topics\/human-african-trypanosomiasis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zrein, M., Granjon, E., Gueyffier, L., Caillaudeau, J., Liehl, P., Pottel, H., Cardoso, C.S., Oliveira, C.D.L., De Oliveira, L.C., and Lee, T.-H. (2018). A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006226"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.2147\/DDDT.S90208","article-title":"Translational challenges of animal models in Chagas disease drug development: A review","volume":"9","author":"Chatelain","year":"2015","journal-title":"Drug. Des. Dev. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez, C., Cucunub\u00e1, Z., Fl\u00f3rez, C., Olivera, M., Valencia, C., Zambrano, P., Le\u00f3n, C., and Ram\u00edrez, J.D. (2016). Molecular Diagnosis of Chagas Disease in Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and Chronic Phases. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004997"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01242-20","DOI":"10.1128\/mBio.01242-20","article-title":"In Vivo Analysis of Trypanosoma cruzi Persistence Foci a Single-Cell Resolution","volume":"11","author":"Ward","year":"2020","journal-title":"Mbio"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/s41598-018-22043-z","article-title":"3-pyridyl inhibitors with novel activity against Trypanosoma cruzi reveal in vitro profiles can aid prediction of putative cytochrome P450 inhibition","volume":"8","author":"Sykes","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sykes, M.L., Baell, J., Kaiser, M., Chatelain, E., Moawad, S.R., Ganame, D., Ioset, J.-R., and Avery, V.M. (2012). Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001896"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: Toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2016.08.003","article-title":"Assessing anti-T. cruzi candidates in vitro for sterile cidality","volume":"6","author":"Cal","year":"2016","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"MacLean, L.M., Thomas, J., Lewis, M.D., Cotillo, I., Gray, D.W., and De Rycker, M. (2018). Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas\u2019 disease drug discovery. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006612"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpddr.2015.10.001","article-title":"Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes","volume":"5","author":"Sykes","year":"2015","journal-title":"Int. J. Parasitol. Drug."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/QCO.0000000000000192","article-title":"The use of posaconazole against Chagas disease","volume":"28","author":"Molina","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP, 51 inhibitors against Trypanosoma cruzi: Implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Riley, J., Brand, S., Voice, M., Caballero, I., Calvo, D., and Read, K.D. (2015). Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. PLoS Neglect. Trop. D, 9.","DOI":"10.1371\/journal.pntd.0004014"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"840768","DOI":"10.4061\/2010\/840768","article-title":"Overview of DNA Repair in Trypanosoma cruzi, Trypanosoma brucei, and Leishmania major","volume":"2010","author":"Machado","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: Substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e02515-18","DOI":"10.1128\/AAC.02515-18","article-title":"Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole","volume":"63","author":"Watson","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1073\/pnas.70.12.3866","article-title":"Mechanism of Puromycin Action\u2014Fate of Ribosomes after Release of Nascent Protein Chains from Polysomes","volume":"70","author":"Azzam","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7284","DOI":"10.1021\/acs.jmedchem.7b00463","article-title":"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi","volume":"60","author":"Brand","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jacobs, R.T., Nare, B., Wring, S.A., Orr, M.D., Chen, D., Sligar, J.M., Jenks, M.X., Noe, R.A., Bowling, T.S., and Mercer, L.T. (2011). SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001151"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.addr.2016.04.029","article-title":"Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions","volume":"101","author":"Lipinski","year":"2016","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1128\/AAC.00498-10","article-title":"Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African Trypanosomiasis","volume":"54","author":"Nare","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/infdis\/jit420","article-title":"New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice","volume":"209","author":"Bustamante","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Svensen, N., Wyllie, S., Gray, D.W., and De Rycker, M. (2021). Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009870"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF","volume":"115","author":"Wall","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9686","DOI":"10.1021\/acs.jmedchem.6b00442","article-title":"Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides","volume":"59","author":"Russell","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e34039","DOI":"10.7554\/eLife.34039","article-title":"Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure","volume":"7","author":"Padilla","year":"2018","journal-title":"eLife"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cmdc.201800755","article-title":"Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease","volume":"14","author":"Veale","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_51","unstructured":"(2022, May 27). MMV Pathogen Box Supporting Information. Available online: https:\/\/www.mmv.org\/mmv-open\/pathogen-box\/pathogen-box-supporting-information."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/00498254.2017.1422156","article-title":"Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes (TM) model","volume":"49","author":"Parmentier","year":"2019","journal-title":"Xenobiotica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/acsinfecdis.5b00026","article-title":"Oxa, Thia, Heterocycle, and Carborane Analogues of SQ109: Bacterial and Protozoal Cell Growth Inhibitors","volume":"1","author":"Li","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1128\/AAC.03972-14","article-title":"SQ109, a New Drug Lead for Chagas Disease","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpddr.2019.01.002","article-title":"Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever","volume":"9","author":"Nyagwange","year":"2019","journal-title":"Int. J. Parasitol. Drug"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"21331","DOI":"10.1039\/c3ra44385j","article-title":"A Divalent Protecting Group for Benzoxaboroles","volume":"44","author":"Vanveller","year":"2013","journal-title":"RSC Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/14756366.2017.1414808","article-title":"Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles","volume":"33","author":"Nocentini","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1087057103008003007","article-title":"Studies on repository compound stability in DMSO under various conditions","volume":"8","author":"Cheng","year":"2003","journal-title":"J. Biomol. Screen."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2174\/138920008786485100","article-title":"In vitro solubility assays in drug discovery","volume":"9","author":"Kerns","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1021\/jm400932c","article-title":"Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: A suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors","volume":"56","author":"Taliani","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"633195w","DOI":"10.3389\/fcell.2021.633195","article-title":"DNA Topoisomerase 3alpha Is Involved in Homologous Recombination Repair and Replication Stress Response in Trypanosoma cruzi","volume":"9","author":"Resende","year":"2021","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/7\/1287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:40:06Z","timestamp":1760139606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/10\/7\/1287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["microorganisms10071287"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms10071287","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]}}}